At Smart Immune, scientists and clinicians have a keen understanding of T cell and NK differentiation with more than 25 years of experience in hematopoiesis and lymphopoiesis.  
Of the 200,000+ patients in the US and Europe that require an allogeneic bone marrow transplant annually, only 25,000 patients have the procedure, and with varying degrees of success. By biomimicking cell differentiation ex vivo, for the first time in human medicine, Smart Immune will introduce allogeneic T-cell progenitors into the patient, which then develop into a full immune repertoire – an ‘off the shelf’ product for personalized medicine. Safer, more effective and more accessible.

Our exclusive ex vivo  lymphoid  technology can differentiate hematopoietic stem cells into T cell progenitors in 7 days instead of the usual 15 months needed in human physiology. Once injected into the patient, ProTcell are able to migrate rapidly to the thymus. The thymus takes just 100 days to select and ‘educate’ these T cell progenitors, personalizing them to the patient and significantly reducing the time to full immune recovery compared with bone marrow transplantation alone. This is a transformational shift in the benefit/risk ratio of allogeneic T cell medicine. The ProTcell platform has potential for enabling a broad range of future applications including CAR ProTcell and TCR ProTcell for long-lasting, targeted immuno-oncology therapies.